



CANCER CENTER SUPPORT
Department of Health and Human Services
National Institutes of Health

Notice of Award

Federal Award Date: 11/21/2019



NATIONAL CANCER INSTITUTE

Grant Number: 5P30CA033572-37
FAIN: P30CA033572

Principal Investigator(s):
STEVEN T. ROSEN, MD

Project Title: Cancer Center Support Grant

Campos, Sylvia
Sr. Grant & Contracts Administrator
1500 E. Duarte Road
Duarte, CA 910103000

Award e-mailed to: sponsres@coh.org

Period Of Performance:
Budget Period: 12/01/2019 – 11/30/2020
Project Period: 08/01/1997 – 11/30/2022

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$3,408,187 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to CITY OF HOPE/BECKMAN RESEARCH INSTITUTE in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number P30CA033572. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Obtained by Rise for Animals. Uploaded 08/19/2020

Page-1

Retrieved from Animal Research Laboratory Overview (ARLO)

Carol Perry
Grants Management Officer
NATIONAL CANCER INSTITUTE

Additional information follows

SECTION I – AWARD DATA – 5P30CA033572-37**Award Calculation (U.S. Dollars)**

Salaries and Wages	\$1,254,207
Fringe Benefits	\$488,411
Personnel Costs (Subtotal)	\$1,742,618
Other	\$227,432

Federal Direct Costs	\$1,970,050
Federal F&A Costs	\$1,438,137
Approved Budget	\$3,408,187
Total Amount of Federal Funds Obligated (Federal Share)	\$3,408,187
TOTAL FEDERAL AWARD AMOUNT	\$3,408,187

AMOUNT OF THIS ACTION (FEDERAL SHARE)	\$3,408,187
----------------------------------------------	--------------------

SUMMARY TOTALS FOR ALL YEARS		
YR	THIS AWARD	CUMULATIVE TOTALS
37	\$3,408,187	\$3,408,187
38	FUTURE COSTS, RECOMMENDED COSTS	
39		

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

CFDA Name: Cancer Centers Support Grants
CFDA Number: 93.397
EIN: 1953432210A1
Document Number: PCA033572J
PMS Account Type: P (Subaccount)
Fiscal Year: 2020

IC	CAN	2020	2021	2022
CA	8423165	\$3,408,187	FUTURE COSTS, RECOMMENDED COSTS	

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:

PCC: 0RMD / **OC:** 41025 / **Released:** PERRYCA 11/20/2019
Award Processed: 11/21/2019 01:00:47 AM

SECTION II – PAYMENT/HOTLINE INFORMATION – 5P30CA033572-37

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III – TERMS AND CONDITIONS – 5P30CA033572-37

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- The grant program legislation and program regulation cited in this Notice of Award.
- Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- 45 CFR Part 75.
- National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- Federal Award Performance Goals: As required by the periodic report in the RPPR or in

- the final progress report when applicable.
- f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part § 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is excluded from Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) P30CA033572. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

This award is not subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

Treatment of Program Income:

Additional Costs

SECTION IV – CA Special Terms and Conditions – 5P30CA033572-37

Clinical Trial Indicator: No

This award does not support any NIH-defined Clinical Trials. See the NIH Grants Policy Statement.

REQUIREMENT: The awardee is required to adhere to the [Cancer Center Support \(CCSG\) Guidelines](#).

REQUIREMENT: The requirements contained in the document, "Intellectual Property Option to Collaborator," are incorporated by reference as a condition of this award. The "Intellectual Property Option to Collaborator" document may be accessed at http://ctep.cancer.gov/industryCollaborations2/docs/Intellectual_Property_Option_to_Collaborator_s.doc or may be obtained from the Regulatory Affairs Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, NCI at (240) 276-6580.

REQUIREMENT: The Beckman Research Institute - City of Hope is required to report all interventional trials supported in whole or in part by this award into the Clinical Trials Reporting Program (CTRP) database. This requirement includes externally peer-reviewed, institutional and industrial trials that utilize the supporting infrastructure of the NCI funded Cancer Center.

REQUIREMENT: The awardee is required to follow the Data Sharing, Model Organisms Sharing, and Data and Safety Monitoring plans included in the competing application and may not implement any changes in the plans without the written prior approval of the National Cancer Institute.

INFORMATION: The Beckman Research Institute - City of Hope has been approved as an NCI-designated Comprehensive Cancer Center in accordance with [PAR17-095](#). The NCI has registered, as a badge, the term "NCI-designated Comprehensive Cancer Center." An approved Center may identify itself accordingly by reflecting the official NCI-designated Comprehensive Cancer Center badge on its stationery and publications.

INFORMATION: This award involves Human Subjects Research. See "Assurance Requirements and Institutional Review Boards" under Part II, Subpart A, Human Subjects, in the [NIH Grants Policy Statement](#), for specific requirements and grantee responsibilities related to the protection of human subjects, which are applicable to and are a term and condition of this award.

This award reflects the National Cancer Institute's acceptance of the certification that all key personnel have completed education on the protection of human subjects, in accordance the [NIH Grants Policy Statement](#), "Education in the Protection of Human Research Subjects."

Any individual involved in the design and conduct of the study that is not included in the certification must satisfy this requirement prior to participating in the project. Failure to comply can result in the suspension and/or termination of this award, withholding of support of the continuation award, audit disallowances, and/or other appropriate action.

INFORMATION: As indicated in the NIH Guide Notice, [NOT-OD-20-003](#) NIH is currently funded through a Continuing Resolution (CR). All legislative mandates that were in effect in FY 2019 (see [NOT-OD-19-030](#) and [NOT-OD-19-036](#)) remain in effect under the CR including the salary limitation set at Executive Level II of the Federal Pay Scale as described in [NOT-OD-19-099](#).

STAFF CONTACTS

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

Grants Management Specialist: Marianne Galczynski
Email: marianne.galczynski@nih.gov **Phone:** 240-276-6300

Program Official: Sonya Roberson
Email: robersons@mail.nih.gov **Phone:** 240-276-6347 **Fax:** 240-276-7682

SPREADSHEET SUMMARY
GRANT NUMBER: 5P30CA033572-37

INSTITUTION: CITY OF HOPE/BECKMAN RESEARCH INSTITUTE

Budget	Year 37	Year 38	Year 39
Salaries and Wages	\$1,254,207	FUTURE COSTS	
Fringe Benefits	\$488,411		
Personnel Costs (Subtotal)	\$1,742,618		
Other	\$227,432		
TOTAL FEDERAL DC	\$1,970,050		
TOTAL FEDERAL F&A	\$1,438,137		
TOTAL COST	\$3,408,187		

Facilities and Administrative Costs	Year 37	Year 38	Year 39
F&A Cost Rate 1	73%	FUTURE COSTS	
F&A Cost Base 1	\$1,970,050		
F&A Costs 1	\$1,438,137		

A. COMPONENT COVER PAGE

Project Title: Small Animal Studies Core
Component Project Lead Information: Wu, Anna M

B. COMPONENT ACCOMPLISHMENTS**B.1 WHAT ARE THE MAJOR GOALS OF THE PROJECT?**

The Small Animal Studies Core (SASC) provides high quality services for basic and translational cancer research to the members of COHCCC via the combined efforts of the Animal Tumor Models and Small Animal Imaging components. The SASC supports both the development and evaluation of state-of-the-art preclinical animal models, providing the necessary expertise and instrumentation for accurate non-invasive tumor evaluation. The SASC staff members collaborate with investigators to perform multimodal imaging for diagnosis and treatment monitoring. The SASC also provides training, equipment maintenance, regulatory compliance support, and ongoing development of advanced animal model techniques in an efficient, cost-effective organizational structure.

Aim 1: To provide consultation for the design, performance, and analysis of animal experiments.

Aim 2: To facilitate the development of new animal models and novel non-invasive in vivo imaging technology in support of cancer research.

Aim 3: To maintain the resources and expertise necessary for conducting animal research with high quality standards and in compliance with local, state, and national guidelines.

B.1.a Have the major goals changed since the Initial competing award or previous report?

No

B.2 WHAT WAS ACCOMPLISHED UNDER THESE GOALS?

File uploaded: FY37-RP_SASC_FINAL.pdf

B.3 COMPETITIVE REVISIONS/ADMINISTRATIVE SUPPLEMENTS

Not Applicable

B.4 WHAT OPPORTUNITIES FOR TRAINING AND PROFESSIONAL DEVELOPMENT HAS THE PROJECT PROVIDED?

NOTHING TO REPORT

B.5 HOW HAVE THE RESULTS BEEN DISSEMINATED TO COMMUNITIES OF INTEREST?

NOTHING TO REPORT

B.6 WHAT DO YOU PLAN TO DO DURING THE NEXT REPORTING PERIOD TO ACCOMPLISH THE GOALS?

1. Continue to develop patient derived xenograft models and humanized mouse models for preclinical trials.
2. Develop patient-derived organoid and 3D cell culture models for precision medicine.
3. Develop canine tumor xenograft models (with Tgen) to facilitate anti-cancer therapeutic development for veterinary medicine and for preclinical trials.

Small Animal Studies Core (SASC)

Facility Director(s): Anna Wu, PhD and Jun Wu, PhD

Leadership

Anna Wu, PhD was appointed Core Director. She replaces Susanta Hui, PhD who served as an interim Director while a national search was conducted. Dr. Hui was reappointed Associate Director for SASC. Dr. Wu rejoins City of Hope after spending the past 15-years at UCLA where she was the Director of the Jonsson Cancer Center's Cancer Molecular Imaging Program. She has an accomplished research career focused on applications of antibodies to cancer diagnosis and therapy.

Key Capabilities

There were no changes in key capabilities during this progress report period.

Key Usage

The SASC had 49 active users during the reporting period, which is a slight decrease from the prior year (51 users). Total usage and percentage of usage and users by type (members with peer-reviewed funding, members without peer-reviewed funding, and non-members) remained unchanged.

C. COMPONENT PRODUCTS**C.1 PUBLICATIONS**

Not Applicable

C.2 WEBSITE(S) OR OTHER INTERNET SITE(S)

Not Applicable

C.3 TECHNOLOGIES OR TECHNIQUES

NOTHING TO REPORT

C.4 INVENTIONS, PATENT APPLICATIONS, AND/OR LICENSES

Not Applicable

C.5 OTHER PRODUCTS AND RESOURCE SHARING

Nothing to report

D. COMPONENT PARTICIPANTS

Not Applicable

E. COMPONENT IMPACT

E.1 WHAT IS THE IMPACT ON THE DEVELOPMENT OF HUMAN RESOURCES?

Not Applicable

E.2 WHAT IS THE IMPACT ON PHYSICAL, INSTITUTIONAL, OR INFORMATION RESOURCES THAT FORM INFRASTRUCTURE?

Not Applicable

E.3 WHAT IS THE IMPACT ON TECHNOLOGY TRANSFER?

NOTHING TO REPORT

E.4 WHAT DOLLAR AMOUNT OF THE AWARD'S BUDGET IS BEING SPENT IN FOREIGN COUNTRY(IES)?

Not Applicable

F. COMPONENT CHANGES**F.1 CHANGES IN APPROACH AND REASONS FOR CHANGE**

Not Applicable

F.2 ACTUAL OR ANTICIPATED CHALLENGES OR DELAYS AND ACTIONS OR PLANS TO RESOLVE THEM

NOTHING TO REPORT

F.3 SIGNIFICANT CHANGES TO HUMAN SUBJECTS, VERTEBRATE ANIMALS, BIOHAZARDS, AND/OR SELECT AGENTS**F.3.a Human Subjects**

No Change

F.3.b Vertebrate Animals

No Change

F.3.c Biohazards

No Change

F.3.d Select Agents

No Change

G. COMPONENT SPECIAL REPORTING REQUIREMENTS

G.1 SPECIAL NOTICE OF AWARD TERMS AND FUNDING OPPORTUNITIES ANNOUNCEMENT REPORTING REQUIREMENTS

Not Applicable

G.2 RESPONSIBLE CONDUCT OF RESEARCH

Not Applicable

G.3 MENTOR'S REPORT OR SPONSOR COMMENTS

Not Applicable

G.4 HUMAN SUBJECTS**G.4.a Does the project involve human subjects?**

No

G.4.b Inclusion Enrollment Data

Not Applicable

G.4.c ClinicalTrials.gov

Not Applicable

G.5 HUMAN SUBJECTS EDUCATION REQUIREMENT

Not Applicable

G.6 HUMAN EMBRYONIC STEM CELLS (HESCS)

Does this project involve human embryonic stem cells (only hESC lines listed as approved in the NIH Registry may be used in NIH funded research)?

No

G.7 VERTEBRATE ANIMALS

Not Applicable

G.8 PROJECT/PERFORMANCE SITES

Not Applicable

G.9 FOREIGN COMPONENT

Not Applicable

G.10 ESTIMATED UNOBLIGATED BALANCE

Not Applicable

G.11 PROGRAM INCOME

Not Applicable

G.12 F&A COSTS

Not Applicable

--

RPPR - Core-8641

RESEARCH & RELATED BUDGET - SECTION A & B FINAL

ORGANIZATIONAL DUNS*: 027176833

Budget Type*: ☒ Project ☐ Subaward/Consortium

Enter name of Organization: BECKMAN RESEARCH INSTITUTE/CITY OF HOPE

Start Date*: 12-01-2019

End Date*: 11-30-2020

A. Senior/Key Person

	Prefix	First Name*	Middle Name	Last Name*	Suffix	Project Role*	Base Salary (\$)	Calendar Months	Academic Months	Summer Months	Requested Salary (\$)*	Fringe Benefits (\$)*	Funds Requested (\$)*
1.		Anna		Wu	PhD	Director	CAL. MONTHS, INST. BASE SALARY				0.00	0.00	0.00
2.		Jun		Wu	PhD	Co-Director					7,478.00	3,283.00	10,761.00
3.		Susanta		Hui	PhD	Associate Director					0.00	0.00	0.00

Total Funds Requested for all Senior Key Persons in the attached file

Additional Senior Key Persons:

File Name:

Total Senior/Key Person

10,761.00

B. Other Personnel

	Number of Personnel*	Project Role*	Calendar Months	Academic Months	Summer Months	Requested Salary (\$)*	Fringe Benefits*	Funds Requested (\$)*
		Post Doctoral Associates						
		Graduate Students						
		Undergraduate Students						
		Secretarial/Clerical						
	1	Technologist	4.8			27,001.00	10,584.00	37,585.00
	1	Total Number Other Personnel					Total Other Personnel	37,585.00
						Total Salary, Wages and Fringe Benefits (A+B)		48,346.00

RESEARCH & RELATED Budget (A-B) (Funds Requested)

RESEARCH & RELATED BUDGET - SECTION C, D, & E

ORGANIZATIONAL DUNS*: 027176833

Budget Type*: ☒ Project ☐ Subaward/Consortium

Enter name of Organization: BECKMAN RESEARCH INSTITUTE/CITY OF HOPE

Start Date*: 12-01-2019

End Date*: 11-30-2020

C. Equipment Description	
List items and dollar amount for each item exceeding \$5,000	
Equipment Item	Funds Requested (\$)*
Total funds requested for all equipment listed in the attached file	0.00
Total Equipment	0.00
Additional Equipment: File Name:	

D. Travel	Funds Requested (\$)*
1. Domestic Travel Costs (Incl. Canada, Mexico, and U.S. Possessions)	0.00
2. Foreign Travel Costs	0.00
Total Travel Cost	0.00

E. Participant/Trainee Support Costs	Funds Requested (\$)*
1. Tuition/Fees/Health Insurance	0.00
2. Stipends	0.00
3. Travel	0.00
4. Subsistence	0.00
5. Other:	
0 Number of Participants/Trainees	Total Participant Trainee Support Costs
	0.00

RESEARCH & RELATED Budget {C-E} (Funds Requested)

RESEARCH & RELATED BUDGET - SECTIONS F-K

ORGANIZATIONAL DUNS*: 027176833

Budget Type*: ☒ Project ☐ Subaward/Consortium

Enter name of Organization: BECKMAN RESEARCH INSTITUTE/CITY OF HOPE

Start Date*: 12-01-2019

End Date*: 11-30-2020

F. Other Direct Costs		Funds Requested (\$)*
1. Materials and Supplies		0.00
2. Publication Costs		0.00
3. Consultant Services		0.00
4. ADP/Computer Services		0.00
5. Subawards/Consortium/Contractual Costs		0.00
6. Equipment or Facility Rental/User Fees		0.00
7. Alterations and Renovations		0.00
Total Other Direct Costs		0.00

G. Direct Costs	Funds Requested (\$)*
Total Direct Costs (A thru F)	48,346.00

H. Indirect Costs			
Indirect Cost Type	Indirect Cost Rate (%)	Indirect Cost Base (\$)	Funds Requested (\$)*
1. MTDC	73.0	48,346.00	35,293.00
Total Indirect Costs			35,293.00
Cognizant Federal Agency			
(Agency Name, POC Name, and POC Phone Number)			

I. Total Direct and Indirect Costs	Funds Requested (\$)*
Total Direct and Indirect Institutional Costs (G + H)	83,639.00

J. Fee	Funds Requested (\$)*
	0.00

K. Budget Justification*	File Name: FY37- BudgetJustification_SASC_FINAL.pdf (Only attach one file.)
--------------------------	-----------------------------------------------------------------------------------

RESEARCH & RELATED Budget (F-K) (Funds Requested)

Budget Justification

Anna Wu, PhD, replaced Susanta Hui, PhD as Director of SASC. Dr. Wu will devote CM. Dr. Hui will continue to serve as Associate Director and devote CM.

Explanation of estimated unobligated balance (including prior carryover) that is greater than 25% of the current year's total budget.

We do not anticipate an unobligated balance greater than 25% of the current year's total budget.